Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

Pfizer Ltd has reported an 85% jump in net profit at ₹330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer.

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova Pfizer Inc. plans to spend ...

Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings—Live ...

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental ...

It did not take long for Pfizer Inc. (NYSE:PFE) to change its mind on its oncology pipeline approach – after the deal with Summit Therapeutics Inc. (SMMT) in February for co-development of ...

Lawmakers are investigating whether Pfizer waited to share results of the Covid vaccine in 2020 until after that year’s presidential election, based on new allegations that a former Pfizer ...

Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation rights in China. 3SBio said separately that the drug has received clearance from the U ...

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones ...

(Reuters) -Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug ...